Incyte

Products

Category

Product

Brand

Description

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023 (PHM263B)

Jakafi (ruxolitinib)		It is Incyte's flagship product and is prescribed for conditions like myelofibrosis, polycythemia vera, and graft-versus-host disease. It has been on the market since 2011.
Opzelura (ruxolitinib cream)		This topical treatment for atopic dermatitis and vitiligo was approved in 2021 and is gaining traction in the dermatology market.
Pemazyre (pemigatinib)		This product was approved for treating cholangiocarcinoma with specific FGFR2 genetic alterations in 2020. It works by targeting and inhibiting the FGFR2 pathway, which plays a role in cancer cell proliferation.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment